ABBOTT PARK, Ill., June 20, 2011 /PRNewswire/ -- Abbott announced today that the U.S. Food and Drug Administration (FDA) has approved a new 45 mg for six-month administration formulation of Lupron ...
ABBOTT PARK, Ill., Aug. 16, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has approved two new strengths for three-month administration of ...
Abbott announced that the US Food and Drug Administration (FDA) has approved two new strengths for three-month administration of Lupron Depot-PED (leuprolide acetate for depot suspension) for the ...
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/cvwck3/lupron_depot) has announced the addition of GlobalData's new report ...
More than 10,000 adverse event reports complaining about the side effects of a commonly used drug called Lupron have been filed with the Food and Drug Administration, according to a recent report by ...
David Geier, the man appointed by Health and Human Services Secretary Robert F. Kennedy Jr. to lead a federal study on the causes of autism, previously treated autistic children with puberty-blocking ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results